American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer

Al B. Benson(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Daniel G. Haller(American Society of Clinical Oncology), Patrick J. Flynn(American Society of Clinical Oncology), Melissa Brouwers(American Society of Clinical Oncology), Mark R. Somerfield(American Society of Clinical Oncology), Manya Charette(American Society of Clinical Oncology), Deborah Schrag(Memorial Sloan Kettering Cancer Center), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Monika K. Krzyzanowska(American Society of Clinical Oncology), Jean A. Maroun(American Society of Clinical Oncology), Alfred M. Cohen(American Society of Clinical Oncology), A Figueredo(American Society of Clinical Oncology), Pamela K. McAllister(American Society of Clinical Oncology)
Journal of Clinical Oncology
June 17, 2004
10.1200/jco.2004.05.063
Cited by 1,451

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
How To Build and Interpret a Nomogram for Cancer Prognosis
|Journal of Clinical Oncology|2008|3.4k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k